Tagged with IP

MEA As global pharmaceutical strategies continue to shift, Ali Sleiman reflects on how Genesys Pharmaceuticals is being built as a disciplined execution platform for the Middle East and Africa. The interview explores how distributor-led models, portfolio selectivity, and strong infrastructure shape access to innovation, including in rare diseases, against an increasingly…

LatAm Dirk van Niekerk, President and CEO of Boehringer Ingelheim South America, identifies Latin America as a pivotal growth engine. Focusing on cardio, renal, metabolic and oncology pillars, the firm is navigating patent gaps through innovative stroke care networks and advanced data analytics, while championing regional talent and sustainable healthcare delivery.…

France Denmark and France are intensifying their cooperation in life sciences at a time when resilience, innovation and industrial capacity have become strategic priorities for Europe. In this interview, Hanne Fugl Eskjær, Denmark’s Ambassador to France, reflects on how complementary strengths in research, digital health and public-private collaboration are shaping a…

USA North Carolina has become a focal point for the next phase of biopharmaceutical manufacturing, and FUJIFILM Biotechnologies is placing a significant bet on that momentum. Laurie Braxton discusses how the combination of large-scale capacity, experienced talent, and a tightly integrated site network is shaping a long-term manufacturing platform designed for…

USA Adriana Herrera, CEO of Pierre Fabre Pharmaceuticals Inc, discusses Pierre Fabre’s dedicated expansion into the US market and the unique strategies guiding its next phase of growth. Drawing on more than two decades of leadership experience across global biopharma organizations, Herrera reflects on building a purpose-driven organization, establishing credibility beyond…

Taiwan In 2024, Taipei Medical University reached a defining milestone. President Mai-Szu Wu oversaw a full digital transformation linking seven affiliated medical institutions and more than 3,000 beds into a unified data platform, creating a foundation for large-scale research, AI applications, and faster clinical-trial operations. This momentum has now extended nationwide…

LatAm Carlos Abelleyra leads Medix, a 70-year-old Mexican pharmaceutical company undergoing a major strategic transformation. Since 2024, he has diversified the firm beyond its historical obesity focus, establishing divisions in vitamins, gastrointestinal products, and women’s health. With a landmark Biocon licensing deal for GLP-1 therapies and plans to launch 30 new…

UAE Adeeb Al Attar leads Genpharm at a point where rare and advanced therapies in the Middle East face a more exacting test. Scale and ambition are no longer enough. What matters now is execution, credibility, and the ability to move innovation through complex healthcare systems without losing focus. In this…

France Kyowa Kirin’s new head for France and Benelux steps into the role at a time when rare diseases, regulatory expectations and scientific modalities are all shifting at speed. In this interview, Aurelie-Anne Chausse reflects on the recent strategic transition toward a fully rare-disease-focused organisation, the growing pressure to identify patients…

Taiwan Jayashri Kulkarni Managing Director of Johnson & Johnson Taiwan, brings 27 years of experience across pharmaceuticals and medical technology in Asia Pacific. Since assuming her Taiwan role , she has focused on outcome-based healthcare, patient advocacy, and leadership development, bringing a perspective that bridges emerging market innovation with healthcare system…

Taiwan With Takeda preparing for global leadership change and Taiwan rapidly upgrading its innovation and access frameworks, General Manager Alexis Lin is navigating one of the most pivotal periods in the affiliate’s 64-year history. Drawing on a career that began far from pharma, she has reshaped Takeda Taiwan into a regional…

Taiwan Nick Wang, General Manager of Daiichi Sankyo Taiwan, has more than 25 years’ experience across clinical research and commercial leadership. Since joining the company in 2020, he has led the build-out of its oncology business while steering the affiliate’s transition to a full-function organisation, with a clear focus on lifecycle…